Table 1.
Patients and their classification according to responses based on disease activity score and C-reactive protein level after 12 weeks of infliximab treatment
| Patient ID number | DAS28 | Δ DAS | EULAR DAS28 responsea | CRP mg/L | Δ CRP | ||
| Baseline (T0) | Week 12 (T12) | Baseline (T0) | Week 12 (T12) | ||||
| 10611 | 5.7 | 5.2 | 0.5 | NR | 4.3 | 29.1 | -24.8 |
| 10612 | 6.2 | 7.6 | -1.4 | NR | 37.4 | 139.0 | -101.6 |
| 10613 | 5.8 | 3.6 | 2.3 | R | 13.0 | 9.0 | 4.0 |
| 10616 | 6.8 | 3.9 | 2.9 | R | 46.0 | 1.0 | 45.0 |
| 10618 | 6.3 | 3.8 | 2.5 | NRb | 43.3 | 52.0 | -8.7 |
| 10619 | 3.2 | 3.7 | -0.5 | NR | 6.0 | 8.0 | -2.0 |
| 10620 | 4.9 | 5.1 | -0.2 | NR | 17.1 | 2.3 | 14.8 |
| 10621 | 3.8 | 4.2 | -0.5 | NR | 68.0 | 68.0 | 0.0 |
| 10622 | 6.0 | 6.6 | -0.6 | NR | 24.4 | 86.2 | -61.8 |
| 10623 | 6.2 | 4.5 | 1.7 | R | 51.3 | 12.4 | 38.9 |
aPatients were deemed to be European League Against Rheumatism (EULAR) responders (Rs) if they had a reduction in DAS28 of greater than or equal to 1.2; all others were considered non-responders (NRs) for analysis purposes. bSubject 10618 achieved a reduction in DAS28 of 2.5, but C-reactive protein (CRP) level increased at T12; thus, to ensure homogeneity in the R group, we excluded this patient from the group. DAS, disease activity score; DAS28, disease activity score using 28 joint counts.